SELLAS Life Sciences Group, Inc. (SLS)

1,4750 +0,0050 (+0,34%) Ab 10:55AM EDT. Markt geöffnet.

SELLAS Life Sciences Group, Inc.

Times Square Tower
Suite 2503 7 Times Square
New York, NY 10036
United States
646 200 5278
https://www.sellaslifesciences.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 16

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Angelos M. Stergiou M.D., ScD h.c.	Founder, President, CEO & Director	904,24k	N/A	1976
Mr. John Thomas Burns CPA	Senior VP & CFO	505,16k	N/A	1985
Ms. Stacy E. Yeung	VP, Associate General Counsel & Head of Compliance	N/A	N/A	N/A
Dr. Dragan Cicic M.D., MBA	Senior Vice President of Clinical Development	466,43k	N/A	1963
Mr. Andrew Elnatan	VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Corporate Governance

SELLAS Life Sciences Group, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.